Medical Oncology Unit 1, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milano, Italy.
Operative Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Via del Pozzo 71, 41124 Modena, Italy.
Cancers (Basel). 2014 Oct 13;6(4):2100-15. doi: 10.3390/cancers6042100.
Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC.
小细胞肺癌（SCLC）是最具侵袭性的肺癌之一。大多数 SCLC 患者在晚期被诊断出来。这种肿瘤类型对化疗和放疗非常敏感，反应率非常高，但总是会复发。此时，治疗选择仍然有限，这些患者的预后较差。对 SCLC 分子生物学的更好了解使我们能够确定潜在的可用药靶点。其中，MET/HGF 轴似乎是涉及 SCLC 侵袭性和进展的最异常信号通路之一。在这篇综述中，我们简要描述了 SCLC 所有最新的分子谱研究文献；特别是，我们讨论了涉及 c-MET 基因的特定改变及其作为 SCLC 潜在靶点的意义。
